Items where authors include "Katoh, N."

Article

Simpson, E.L., Blauvelt, A., Silverberg, J.I. et al. (5 more authors) (2024) Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate-to-severe atopic dermatitis who do not achieve IGA 0/1. American Journal of Clinical Dermatology, 25. pp. 139-148. ISSN 1175-0561

Siegfried, E.C., Cork, M.J., Katoh, N. et al. (6 more authors) (2023) Dupilumab provides clinically meaningful responses in children aged 6–11 years with severe atopic dermatitis: post hoc analysis results from a phase III trial. American Journal of Clinical Dermatology, 24 (5). pp. 787-798. ISSN 1175-0561

Zuberbier, T. orcid.org/0000-0002-1466-8875, Abdul Latiff, A., Aggelidis, X. orcid.org/0000-0003-1715-3022 et al. (105 more authors) (2023) A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative. Clinical and Translational Allergy, 13 (9). e12299. ISSN 2045-7022

Zuberbier, T. orcid.org/0000-0002-1466-8875, Beck, L.A., Bedbrook, A. et al. (12 more authors) (2023) Developing integrated care pathways for atopic dermatitis—challenges and unmet needs. Clinical and Translational Allergy, 13 (3). e12236. ISSN 2045-7022

Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E. et al. (19 more authors) (2021) Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). British Journal of Dermatology, 184 (3). pp. 437-449. ISSN 0007-0963